Mr. Boris Jordan reports

CURALEAF INTERNATIONAL LAUNCHES A RANGE OF MEDICAL CANNABIS PRODUCTS IN AUSTRALIA

Curaleaf International, part of Curaleaf Holdings Inc., has launched Curaleaf branded products in Australia. This announcement marks the expansion of Curaleaf's presence in one of the world's fastest-growing medical cannabis markets and underscores its commitment to local collaboration, clinical integrity and patient care.

The initial product offering, comprising four cannabis flower strains, will be distributed through Canngea, a licensed Australian manufacturer and wholesaler with a wealth of experience in medical cannabis. This partnership supports Curaleaf's vision to be the world's leading cannabis company by consistently delivering superior products and services.

Over the coming months, patients and health care professionals in Australia can look forward to a broader portfolio and further innovative solutions offered by Curaleaf, including precision-dosed inhalation formats and popular strains already widely prescribed across the United Kingdom, Germany and other key European markets.

Juan Martinez, head of Curaleaf International, commented: "Entering the Australian market is a significant milestone in our global strategy to expand access to high-quality, evidence-backed cannabis medicines. We're committed to supporting Australian patients and health care professionals with reliable, consistent products and the backing of one of the industry's most advanced supply chains."

Boris Jordan, chairman and chief executive officer of Curaleaf, added: "Australia is an exciting and rapidly evolving market, expected to surpass $1-billion in annual sales next year, and this launch is a positive step forward in our strategy to extend our position as the global leader in cannabis. We're bringing a proven portfolio and a strong track record of innovation, with more to come."

About Curaleaf International

Curaleaf International is shaping the future of cannabis through its commitment to research and product excellence. Powered by a strong presence at all stages of the supply chain, its unique distribution network throughout Europe, Canada and Australasia brings together pioneering research with cutting-edge cultivation, extraction and production. Amidst a rapid growth trajectory, the emphasis on quality and expertise aims to ensure the delivery of safe and legal cannabis.

Curaleaf International's network includes a clinic, pharmacy and laboratory in the United Kingdom; cultivation and European Union good manufacturing practice processing facilities in Portugal; an EU GMP processing, quality assurance and research site in Spain; Four20 Pharma wholesaler and distributor in Germany; a Polish wholesaler and clinic; and the EU GMP producer Northern Green Canada.

Curaleaf International is part of Curaleaf Holdings, a leading international producer and distributor of consumer cannabis products.